GlassScriptPhysician profile
Chelsea Gray
NPI 1801411731
$521.97
in general payments reported to CMS, 2019-2025
12 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.76 · 2022: $91.52 · 2023: $87.86 · 2024: $160 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $190 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $190.20 |
| Education | $186.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $138.38 | 2023-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $129.03 | 2024 | Uzedy |
| Abbvie INC. | $62.79 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.35 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $25.07 | 2025 | Abilify Asimtufii, Abilify Maintena |
| Collegium Pharmaceutical, INC. | $24.55 | 2025 | Jornay Pm |
| Alkermes, INC. | $17.80 | 2025 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $17.48 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.01 | 2021 | |
| Neurocrine Biosciences, INC. | $13.85 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.80 | 2024 | |
| Supernus Pharmaceuticals, INC. | $12.86 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.